Monday's top analyst upgrades, downgrades and initiations include AbbVie, Alcoa, Apple, Deckers Outdoor, Dish Network, Pfizer and Petrobras.
Here is a look at the top performers for 2014, nine stocks that have doubled and have a current market cap of at least $5 billion.
Monday's top analyst upgrades, downgrades and initiations include Alcoa, American Airlines, CONSOL Energy, Deere, DreamWorks Animation, Groupon, Seadrill and Yahoo!
Botox maker Allergan has entered a definitive agreement to be acquired by Actavis, despite higher offer from Valeant Pharmaceuticals.
Hedge fund ValueAct Capital Management has disclosed acquisition of 5.7% stake in Agrium.
A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could be of the blockbuster variety.
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Wednesday, July 23, 2014. They include DuPont, General Electric, King, Microsoft, Xilinx and McDonald's.
In a sharply worded press release Monday morning, Valeant Pharmaceuticals said that it "can no longer tolerate" statements from Allergan that are "attempts to mislead investors."
ThinkstockHedge fund manager John Paulson spoke at the CNBC Institutional Investor Delivering Alpha conference on Wednesday, offering keen insight in the current merger environment. Paulson signaled that Valeant Pharmaceuticals International Inc. (NYSE:…
ThinkstockCanada-based Valeant Pharmaceuticals Inc. (NYSE: VRX) has raised its offer for Allergan Inc. (NYSE: AGN) for the second time this week. The latest offer, announced just minutes ago includes $72 a share…
Allergan has been a great company, and it can still be one in the future. The question is whether this greatness will be as an independent company or as a subsidiary of…
The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top stocks started with a rating of Buy at Jefferies.
Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone rangers when it came to the…
The biotech and specialty pharmaceutical groups got hit hard Thursday for a variety of reasons. The largest of which the analysts at Jefferies believe, is commentary within Washington's new budget proposal regarding…
ThinkstockTypically, specialty pharmaceutical companies either provide generic versions of former top-selling branded drugs or they may focus on drugs that target rare or hard to treat diseases as orphan drug manufacturers. One…
